A retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE)
- 15 January 1994
- Vol. 73 (2) , 470-475
- https://doi.org/10.1002/1097-0142(19940115)73:2<470::aid-cncr2820730236>3.0.co;2-7
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Carcinoma of unknown primary: Identification of a treatable subset?Annals of Oncology, 1990
- Carcinoma of unknown primary siteAnnals of Oncology, 1990
- Metastatic Adenocarcinomas of Unknown Primary SiteAmerican Journal of Clinical Oncology, 1990
- Early Metastatic Cancer of Unknown Primary Origin at PresentationArchives of internal medicine (1960), 1988
- Poorly Differentiated Neuroendocrine Carcinoma of Unknown Primary SiteAnnals of Internal Medicine, 1988
- Curative Combination Chemotherapy for Patients with Advanced Poorly Differentiated Carcinoma of Unknown Primary SiteAmerican Journal of Clinical Oncology, 1988
- Acups (adenocarcinoma of unknown primary site): A clinical and cost benefit analysisInternational Journal of Radiation Oncology*Biology*Physics, 1987
- Lack of Value for Cisplatin Added to Mitomycin-Doxorubicin Combination Chemotherapy for Carcinoma of Unknown Primary Site A Randomized TrialAmerican Journal of Clinical Oncology, 1987
- An analysis of 1539 patients with cancer of unknown primary siteCancer, 1986
- VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary siteEuropean Journal of Cancer and Clinical Oncology, 1983